PBYI (STOCKS)
PUMA BIOTECHNOLOGY INC
$7.840000
+0.060000 (+0.77%)
Prev close: $7.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Alan H. Auerbach
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $385.39M
- Employees
- 172
- P/E (TTM)
- 12.32
- P/B (TTM)
- 2.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.26 | $0.23 | +0.0285 | +12.31% |
|
Sep 2025 (Q3)
|
$0.17 | $0.05 | +0.1241 | +270.37% |
|
Jun 2025 (Q2)
|
$0.12 | $0.10 | +0.0153 | +14.61% |
|
Mar 2025 (Q1)
|
$0.06 | $-0.02 | +0.0804 | +394.12% |
Financial Statements
| Revenues | $228.37M |
| Benefits Costs and Expenses | $192.59M |
| Cost Of Revenue | $58.16M |
| Costs And Expenses | $191.07M |
| Gross Profit | $170.21M |
| Nonoperating Income/Loss | -$1.52M |
| Operating Expenses | $132.92M |
| Selling, General, and Administrative Expenses | $70.85M |
| Depreciation and Amortization | $10.94M |
| Other Operating Expenses | $51.13M |
| Operating Income/Loss | $37.30M |
| Income/Loss From Continuing Operations After Tax | $31.11M |
| Income/Loss From Continuing Operations Before Tax | $35.78M |
| Income Tax Expense/Benefit | $4.67M |
| Income Tax Expense/Benefit, Current | $1.43M |
| Income Tax Expense/Benefit, Deferred | $3.25M |
| Net Income/Loss | $31.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $31.11M |
| Net Income/Loss Available To Common Stockholders, Basic | $31.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.62 |
| Diluted Earnings Per Share | $0.61 |
| Basic Average Shares | 50,011,485 |
| Diluted Average Shares | 50,653,283 |
| Assets | $216.30M |
| Current Assets | $162.69M |
| Cash | $91.63M |
| Inventory | $5.52M |
| Prepaid Expenses | $3.64M |
| Other Current Assets | $61.90M |
| Noncurrent Assets | $53.62M |
| Fixed Assets | $187.00K |
| Other Non-current Assets | $53.43M |
| Liabilities | $85.96M |
| Current Liabilities | $81.25M |
| Accounts Payable | $5.06M |
| Wages | $5.80M |
| Other Current Liabilities | $70.40M |
| Noncurrent Liabilities | $4.71M |
| Long-term Debt | $22.68M |
| Equity | $130.34M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $130.34M |
| Liabilities And Equity | $216.30M |
| Net Cash Flow From Operating Activities | $41.80M |
| Net Cash Flow From Operating Activities, Continuing | $41.80M |
| Net Cash Flow From Investing Activities | -$36.19M |
| Net Cash Flow From Investing Activities, Continuing | -$36.19M |
| Net Cash Flow From Financing Activities | -$45.20M |
| Net Cash Flow From Financing Activities, Continuing | -$45.20M |
| Net Cash Flow | -$39.58M |
| Net Cash Flow, Continuing | -$39.58M |
| Comprehensive Income/Loss | $31.14M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $31.14M |
| Other Comprehensive Income/Loss | $31.14M |